Belgian Retail Distributors Stock News

ENXTBR:UCB
ENXTBR:UCBPharmaceuticals

Will Lupus PHOENYCS GO Data and Safety Overhaul Change UCB's (ENXTBR:UCB) Narrative

Earlier in June 2026, ELIQUENT Life Sciences announced that UCB went live with the full Veeva Safety Suite, consolidating its global pharmacovigilance operations into a single cloud-based platform delivered in collaboration with Veeva, Pinnaxis, and Daelight Solutions. Separately, UCB and Biogen presented Phase 3 PHOENYCS GO data at EULAR 2026 suggesting dapirolizumab pegol may help systemic lupus erythematosus patients sustain disease control while reducing long-term steroid exposure,...
ENXTBR:DIE
ENXTBR:DIERetail Distributors

A Look At D'Ieteren Group (ENXTBR:DIE) Valuation After Its Latest Dividend Announcement

Dividend announcement and what it means for investors D'Ieteren Group (ENXTBR:DIE) has declared an annual dividend of €1.40 per share, with an ex dividend date on 9 June 2026, record date on 10 June and payment on 11 June. This dividend decision puts income directly on the table for shareholders. It also offers a fresh data point on how management is choosing to return cash alongside the group’s investment focused business model. See our latest analysis for D'Ieteren Group. The dividend news...
ENXTBR:PROX
ENXTBR:PROXTelecom

Proximus Weighs Unifiber Deal As Valuation Gap And Risks Draw Focus

Proximus (ENXTBR:PROX) and Unifiber SA recently held an M&A call indicating interest in a potential transaction. The discussion signals that both companies are assessing options for closer collaboration or corporate action. Details on structure, timing, and financial terms have not been made public. For investors watching Proximus at a share price of €6.61, the prospect of an M&A move with Unifiber SA comes after a mixed share price record. The stock is down 7.6% year to date and down 44.3%...
ENXTBR:ACKB
ENXTBR:ACKBConstruction

Assessing Ackermans & Van Haaren (ENXTBR:ACKB) Valuation After Recent Share Price Softness

Recent performance snapshot for Ackermans & Van Haaren (ENXTBR:ACKB) Ackermans & Van Haaren (ENXTBR:ACKB) has drawn attention after a period where the stock is up 12.7% year to date, yet down 6.5% over the past month and 4.9% over the past 3 months. At a last close of €262.20 and a market value of about €8.57b, the company reports annual revenue of €5,961.61m and net income of €592.55m, with annual revenue growth of 2.18% and net income growth of 5.72%. See our latest analysis for Ackermans &...
ENXTBR:PAY
ENXTBR:PAYElectronic

Payton Planar Magnetics (ENXTBR:PAY) Margin Drop To 20.4% Tests Bullish Narratives

Payton Planar Magnetics (ENXTBR:PAY) has just posted Q1 2026 revenue of US$10.65 million with basic EPS of US$0.08. This sets the tone for how investors will read the latest numbers against a year in which trailing twelve month EPS was US$0.55 on revenue of US$46.83 million. Over recent quarters, revenue has ranged between US$9.61 million and US$13.23 million while quarterly basic EPS has moved between US$0.08 and US$0.20. This gives investors a clear view of how top line and per share...
ENXTBR:UMI
ENXTBR:UMIChemicals

Is It Time To Reassess Umicore (ENXTBR:UMI) After Its 178% One Year Surge?

Wondering if Umicore at €25.62 is offering genuine value or just catching your eye after a strong run? This article breaks down what the current price might be implying. The stock has recently returned 4.9% over 7 days, 50.2% over 30 days, 37.8% year to date, and 178.3% over 1 year, which naturally raises questions about how much of the story is already in the price. Recent coverage has focused on Umicore's position in materials and related technologies, with investors paying close attention...
ENXTBR:KBC
ENXTBR:KBCBanks

3 European Dividend Stocks To Consider With Up To 8% Yield

As European markets experience a notable upswing, with the STOXX Europe 600 Index climbing by 3% amid hopes for geopolitical de-escalation, investors are increasingly seeking stable returns in an environment marked by adjusted growth forecasts and persistent inflation concerns. In such a climate, dividend stocks can offer an attractive option for generating income, as they provide regular payouts that can help offset market volatility and economic uncertainties.
ENXTBR:SYENS
ENXTBR:SYENSChemicals

Is Syensqo (ENXTBR:SYENS) Refocusing Performance & Care to Strengthen Its Specialty Materials Identity?

In the first quarter of 2026, Syensqo reported sales of €1,461 million, with net income improving to €62 million from a small loss a year earlier, and basic earnings per share rising to €0.60. Ahead of these results, the company launched a review of its Performance & Care segment to sharpen its focus on specialty materials and advanced technologies across sectors such as aerospace, electronics, healthcare, energy, and advanced mobility. We’ll now consider how the Performance & Care segment...
ENXTBR:CMBT
ENXTBR:CMBTOil and Gas

Cmb.Tech (ENXTBR:CMBT) Q1 EPS Surge Tests Bearish Margin And Guidance Concerns

Cmb.Tech (ENXTBR:CMBT) opened 2026 with a busy quarter, reporting Q1 revenue of US$807.3 million and basic EPS of US$1.27, while trailing twelve month revenue sat at US$2.2 billion with EPS of US$1.92. This gives investors a fresh read on both quarterly momentum and the rolling earnings base behind the current €14.58 share price. Over recent periods the company has seen revenue move from US$235.0 million in Q1 2025 and US$226.0 million in Q4 2024 to US$807.3 million in Q1 2026, with basic EPS...
ENXTBR:PROX
ENXTBR:PROXTelecom

Will Weaker Q1 2026 Earnings Momentum Change Proximus' (ENXTBR:PROX) Investment Narrative?

Proximus PLC has reported past first-quarter 2026 results showing sales of €1,510 million and revenue of €1,525 million, with net income of €124 million and basic earnings per share from continuing operations of €0.38, all lower than the same period a year earlier. This broad-based decline across sales, revenue and earnings measures raises questions about how effectively Proximus’s existing efficiency programs and investment plans are offsetting current pressures on its business. We’ll now...
ENXTBR:VGP
ENXTBR:VGPReal Estate

Assessing VGP (ENXTBR:VGP) Valuation After Recent Share Price Weakness

Recent share performance and business context VGP (ENXTBR:VGP) has drawn investor attention after the stock declined 10.2% over the past day, extending falls of 5.6% over the past week and 11.3% over the past month. Those moves come as the €2.21b logistics and semi industrial real estate company, headquartered in Antwerp, continues to generate revenue of €191.99m and net income of €290.44m. This performance is partly supported by its renewable energy activities. See our latest analysis for...
ENXTBR:VIO
ENXTBR:VIOMetals and Mining

Assessing Viohalco (ENXTBR:VIO) Valuation After Investor Interest In Its Diversified Metals And Cables Operations

Viohalco (ENXTBR:VIO) drew attention after its stock climbed 13.55% in after-hours trading on EURONEXT on 7 May, as investors focused on its aluminium, copper, cables, and steel operations. See our latest analysis for Viohalco. That after hours jump adds to strong recent momentum, with a 7 day share price return of 16.45% and a 30 day share price return of 23.60%. The 1 year total shareholder return of 218.26% and 5 year total shareholder return of 288.09% underline how sentiment has shifted...
ENXTBR:ARGX
ENXTBR:ARGXBiotechs

Argenx Leadership Shift And Vyvgart Milestones Reshape Autoimmune Growth Story

argenx (ENXTBR:ARGX) appointed Karen Massey as CEO, and co founder Tim Van Hauwermeiren moved to Chairperson. The company reported strong Q1 results, with accelerating VYVGART sales highlighted as a key driver. An FDA decision on a potential Vyvgart label expansion in seronegative generalized myasthenia gravis is expected soon. argenx focuses on antibody based therapies for autoimmune diseases, with VYVGART already a central product in its portfolio. For investors watching the immunology...
ENXTBR:SYENS
ENXTBR:SYENSChemicals

Syensqo Share Cancellation Reshapes Ownership As Valuation Gap Persists

Syensqo cancelled a significant number of shares it had repurchased as part of its ongoing buyback program. The move changes the total number of outstanding shares and voting rights for ENXTBR:SYENS. The action forms part of a broader capital management approach that affects how ownership is distributed across shareholders. For investors watching ENXTBR:SYENS, the cancellation of repurchased shares directly alters the share count that sits behind the current €57.3 price. Recent performance...